Health Canada has granted a Notice of Compliance (NOC) for Enhertu® (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class of therapeutics called ...

We project that in the next six weeks, the probability of a U.S. recession getting started in the next twelve months will be ...

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Daiichi Sankyo Company (DSKYF) is currently conducting a ...

Researchers present an overview of treatment and management strategies for patients with HR+/HER2+ breast cancer, including common adverse effects.

Nkarta CEO Paul Hastings recently spoke to the importance of the industry's collaborations with Chinese biopharma companies.

Two phase 3 trials suggest that the antibody drug conjugate led to significantly improved outcomes in both the neoadjuvant ...

Approved targeted drugs for HER2 -mutant NSCLC include trastuzumab deruxtecan (T-DXd, Enhertu) -- which is highly effective ...

Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced it has entered into a research ...

and the DxD Hub Diagnomics Centre. The company is equally committed to diversity, equity, and inclusion, demonstrated through ...

BERLIN -- Antibody-drug conjugates (ADCs) targeting Trop2 made a strong case as first-line standard of care for metastatic ...

Daiichi and Merck saw the highest ORR—57.1%—in patients who received the top dose of R-DXd. Yet the drugmakers have opted to take the middle 5.6-mg/kg dose into the phase 3 part of the trial. The ORR ...